Role of platelets in inflammation and cancer; novel therapeutic strategies
“The results of clinical studies have shown that the antiplatelet drug aspirin reduces the incidence of vascular events and colorectal cancer.”
“Low-dose aspirin treatment (which is associated with a preferential inhibition of platelet COX-1) causes a 70-80% reduction of urinary 11-dehydro-TXB2 and 2,3-din-or-TXB2 excretion.”
"Moreover, the results of clinical studies have shown that the antiplatelet drug aspirin reduces the incidence of vascular events and colorectal cancer. All these pieces of evidence support the notion that colorectal cancer and atherothrombosis may share a common mechanism of disease, that is, platelet activation in response to epithelial (in tumourigensis) and endothelial (in tumourgenesis and atherothrombosis) injury."
Read More